Initial orientation

Demographics, gender distribution, age distribution, time of diagnosis in DACH (Germany, Austria, Switzerland).

Processed data on incidence, gender distribution, age peak and research funding.

A fact sheet from the LCD (as of May 2022) on LC. It covers current studies, outpatient care and rehabilitation, as well as research and therapy.

A medical overview of Long Covid, including diagnostic procedures, medical guidelines, continuing education opportunities, and statements from medical organizations on LC.

Pathophysiology

Studies have identified numerous abnormalities that point to an organic cause of ME/CFS.

MECFSmed demystifies ME/CFS to equip healthcare professionals and patients with the tools and knowledge they need for effective treatment strategies, and provides a directory of healthcare professionals to facilitate the search for appropriate medical care.

The National Association of Statutory Health Insurance Physicians (KBV) hereby issues the following statement on the motion submitted by the CDU/CSU parliamentary group in the Bundestag, printed paper 20/4886 dated 14 December 2022, "Helping ME/CFS sufferers and their families – For better healthcare and therapy provision, education and recognition".

If the prevalence estimates from four studies based on criteria catalogues with PEM as the leading symptom are applied directly to the German population, the number of patients with ME/CFS in Germany can be estimated at between approximately 140,000 and approximately 310,000. It seems plausible to assume that the SARS-CoV-2 pandemic may lead to an increase in the prevalence of ME/CFS, as some post-COVID patients meet the diagnostic criteria for ME/CFS.

​

(Page -IV-)

In-depth insight into symptoms, comorbidities and treatment approaches in English.

Overview of symptoms, therapies, diagnosis and coping with ME/CFS.

ME/CFS is one of the last major diseases that has hardly been researched. Here is an initial overview.

Statistical analysis by the University of Frankfurt from 2023 on the economic costs of Long Covid.

The following overview of current publications on this topic for other countries shows that an economic loss in Germany of approximately €7.4 billion per year is a realistic estimate. This contrasts with official funding for ME/CFS research of €0.

A first informative overview of what Long Covid actually is. It points out that LC can often progress to ME/CFS after a longer period.